分子診斷的共同研究及授權契約:2016年～2025年

"分子診斷領域的合作與許可交易" 報告提供了前所未有的途徑，讓我們能夠全面了解全球領先生物製藥公司達成的分子診斷交易。

本報告詳細介紹了2016年至2025年的分子診斷交易，並詳細解讀和分析了企業達成分子診斷交易的方式和原因。這些交易往往涉及多個領域，從合作研發到成果商業化，應有盡有。

本報告涵蓋了合作、開發、研究和授權交易。它提供了自 2016 年以來宣布的 759 筆分子診斷交易的綜合清單。此外，它還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件（如有）。

本報告第一章介紹了分子診斷交易。

第一章是對報告的介紹。

第二章概述了自 2016 年以來的分子診斷交易活動。

第三章概述了自 2016 年以來的主要分子診斷交易。交易按標題價值列出。

第四章提供了在分子診斷交易中最活躍的 25 家公司的綜合列表，隨後是簡要摘要和分子診斷交易的綜合列表，以及上市公司可用的合約文件。

第五章全面深入地回顧了自2016年1月以來達成和宣布的分子診斷交易，並提供了公開的合約文件。

第六章全面深入地回顧了自2016年1月以來達成和宣布的分子診斷夥伴關係。本章按感興趣的特定分子診斷技術類型進行組織。

此外，報告還包含大量圖表和數據，展示了自2016年以來的分子診斷交易活動。

此外，綜合交易目錄按公司A-Z、交易類型和治療目標進行組織。每個交易標題都透過網頁連結連結到線上交易記錄，並且（如有）還包含合約文件，方便在需要時輕鬆存取每份協議文件。

主要的優點

"分子診斷領域的合作與授權協議" 提供讀者以下主要優勢：

• 了解自2016年以來的交易趨勢
• 瀏覽分子診斷領域的合作與授權交易
• 基準分析 - 確定交易的市場價值
• 財務條款 - 一次性付款、里程碑付款、特許權使用費
• 依公司A-Z、交易類型及治療領域排列的交易目錄
• 主要交易價值
• 最活躍的交易者
• 確定每筆交易的資產和交易條款
• 存取合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款是否適合您的合作公司
• 節省數百小時的研究時間

研究範圍

• 分子 "分子診斷合作與授權協議" 旨在深入了解全球領先生物製藥公司達成的分子診斷趨勢和交易結構。

分子診斷合作與授權協議包括：

• 生物製藥產業的分子診斷交易趨勢
• 涵蓋製藥和生物技術領域的分子診斷交易記錄目錄
• 主要分子診斷交易
• 最活躍的分子診斷許可交易商
• "分子診斷合作與許可協議" 提供全面的交易記錄存取權限，包括合約文件（如有）。

對協議進行分析有助於進行盡職調查：

• 授予或選擇的具體權利是什麼？
• 實際授予合約夥伴哪些權利？
• 授予了哪些獨家權利？
• 合約的付款結構是怎樣的？
• 如何審計銷售和付款？
• 合約期限是多久？
• 合約的關鍵條款是如何定義的？
• 知識產權如何處理歸屬於誰？
• 誰負責商業化？
• 誰負責開發、供應和製造？
• 如何管理保密和資訊揭露？
• 如何解決爭議？
• 合約在什麼情況下可以終止？
• 如果所有權發生變更會怎樣？
• 雙方約定了哪些再授權和分包條款？
• 公司堅持哪些標準條款？
• 哪些標準條款在不同合作夥伴或不同交易類型之間似乎有所不同？
• 公司在契約法方面主張哪些管轄權？

目錄

摘要整理

第1章 簡介

第2章 分子診斷交易趨勢

• 簡介
• 多年的分子診斷交易
• 最活躍的分子診斷交易業者
• 分子診斷交易，類別
• 分子診斷交易，各治療領域
• 分子診斷交易，各業界
• 分子診斷交易的交易條件
  • 分子診斷交易的標題價值
  • 分子診斷交易預付款
  • 分子診斷交易的里程金
  • 分子診斷權利金費率

第3章 -主要分子診斷交易

• 簡介
• 分子診斷相關的首位交易額

第4章 -最活躍的分子診斷交易業者

• 簡介
• 最活躍的分子診斷交易業者
• 最活躍的分子診斷交易企業簡介

第5章 分子診斷契約交易名錄

• 簡介
• 分子診斷契約交易名錄

第6章 各技術類型的分子診斷交易

• 交易名錄
• 交易名錄- 分子診斷交易(AZ)，各企業
• 交易名錄- 分子診斷交易，各交易類型
• 交易名錄- 分子診斷交易，各治療領域
• 交易類型定義
• 關於調查公司
• 目前聯盟
• 目前契約
• 最近的報告標題

Molecular Diagnostics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the molecular diagnostics deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of molecular diagnostics deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 759 molecular diagnostics deals announced since 2016 including financial terms where available including links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of molecular diagnostics dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in molecular diagnostics dealmaking since 2016.

Chapter 3 provides an overview of the leading molecular diagnostics deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in molecular diagnostics dealmaking with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of molecular diagnostics deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific molecular diagnostics technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in molecular diagnostics deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Molecular Diagnostics Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse molecular diagnostics collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Molecular Diagnostics Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of molecular diagnostics trends and structure of deals entered into by leading biopharma companies worldwide.

Molecular Diagnostics Collaboration and Licensing Deals includes:

• Trends in molecular diagnostics dealmaking in the biopharma industry
• Directory of molecular diagnostics deal records covering pharmaceutical and biotechnology
• The leading molecular diagnostics deals by value
• Most active molecular diagnostics licensing dealmakers
• Molecular Diagnostics Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in molecular diagnostics dealmaking

• 2.1. Introduction
• 2.2. Molecular diagnostics deals over the years
• 2.3. Most active molecular diagnostics dealmakers
• 2.4. Molecular diagnostics deals by deal type
• 2.5. Molecular diagnostics deals by therapy area
• 2.6. Molecular diagnostics deals by industry sector
• 2.7. Deal terms for molecular diagnostics deals
  • 2.7.1 Molecular diagnostics deals headline values
  • 2.7.2 Molecular diagnostics deal upfront payments
  • 2.7.3 Molecular diagnostics deal milestone payments
  • 2.7.4 Molecular diagnostics royalty rates

Chapter 3 - Leading molecular diagnostics deals

• 3.1. Introduction
• 3.2. Top molecular diagnostics deals by value

Chapter 4 - Most active molecular diagnostics dealmakers

• 4.1. Introduction
• 4.2. Most active molecular diagnostics dealmakers
• 4.3. Most active molecular diagnostics deals company profiles

Chapter 5 - Molecular diagnostics contracts dealmaking directory

• 5.1. Introduction
• 5.2. Molecular diagnostics contracts dealmaking directory

Chapter 6 - Molecular diagnostics dealmaking by technology type

• Deal directory
• Deal directory - Molecular diagnostics deals by company A-Z
• Deal directory - Molecular diagnostics deals by deal type
• Deal directory - Molecular diagnostics deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Molecular diagnostics deals since 2016
• Figure 2: Active molecular diagnostics dealmaking activity - 2016 - 2025
• Figure 3: Molecular diagnostics deals by deal type since 2016
• Figure 4: Molecular diagnostics deals by therapy area since 2016
• Figure 5: Molecular diagnostics deals by industry sector since 2016
• Figure 6: Molecular diagnostics deals with a headline value
• Figure 7: Molecular diagnostics deals with an upfront value
• Figure 8: Molecular diagnostics deals with a milestone value
• Figure 9: Molecular diagnostics deals with a royalty rate value
• Figure 10: Top molecular diagnostics deals by value since 2016
• Figure 11: Most active molecular diagnostics dealmakers 2016 - 2025
• Figure 12: Molecular diagnostics deals by technology type since 2016